Pharmaceutical Topical Compositions

Abstract

The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

1 . A stable topical ointment composition consisting of:
 a) 0.2-5% by weight (based on the total weight of the composition) of ozenoxacin, and   b) a suitable carrier selected from white wax, white soft paraffin, and mixtures thereof.   
     
     
         2 . The stable topical ointment composition according to  claim 1 , wherein the suitable carrier is white soft paraffin. 
     
     
         3 . The stable topical ointment composition according to  claim 1  containing 0.5 to 2% by weight of ozenoxacin. 
     
     
         4 . The stable topical ointment composition according to  claim 3  containing 1% by weight of ozenoxacin. 
     
     
         5 . The stable topical ointment composition according to  claim 1  for use in the treatment or prevention of skin and skin structure infections. 
     
     
         6 . The stable topical ointment composition according to  claim 1  in the treatment of sexually transmitted diseases and genital tract infections. 
     
     
         7 . The stable topical ointment composition according to  claim 1  in the eradication of nasopharynx infections in asymptomatic nasal carriers. 
     
     
         8 . A method for the treatment or prevention of skin and skin structure infections comprising administering the composition according to  claim 1  to a subject in need thereof. 
     
     
         9 . A method for the treatment or prevention of sexually transmitted diseases and genital tract infections comprising administering the composition according to  claim 1  to a subject in need thereof. 
     
     
         10 . A method for eradication of nasopharynx infections in asymptomatic nasal carriers comprising administering the composition according to  claim 1  to a subject in need thereof. 
     
     
         11 . A stable topical ointment composition comprising:
 a) 0.2-5% by weight (based on the total weight of the composition) of ozenoxacin, and   b) a suitable carrier selected from white wax, white soft paraffin, and mixtures thereof.   
     
     
         12 . The stable topical ointment composition according to  claim 11 , wherein the suitable carrier is white soft paraffin. 
     
     
         13 . The stable topical ointment composition according to  claim 11  containing 0.5 to 2% by weight of ozenoxacin. 
     
     
         14 . The stable topical ointment composition according to  claim 13  containing 1% by weight of ozenoxacin. 
     
     
         15 . The stable topical ointment composition according to  claim 11  for use in the treatment or prevention of skin and skin structure infections. 
     
     
         16 . The stable topical ointment composition according to  claim 11  in the treatment of sexually transmitted diseases and genital tract infections. 
     
     
         17 . The stable topical ointment composition according to  claim 11  in the eradication of nasopharynx infections in asymptomatic nasal carriers. 
     
     
         18 . A method for the treatment or prevention of skin and skin structure infections comprising administering the composition according to  claim 11  to a subject in need thereof. 
     
     
         19 . A method for the treatment or prevention of sexually transmitted diseases and genital tract infections comprising administering the composition according to  claim 11  to a subject in need thereof. 
     
     
         20 . A method for eradication of nasopharynx infections in asymptomatic nasal carriers comprising administering the composition according to  claim 11  to a subject in need thereof.